alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 476–500 of 504 studies in Mild cognitive impairment · free to read (page 20 of 21) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Mild cognitive impairment” covers

Mild cognitive impairment — The stage between normal ageing and dementia: who progresses, who doesn't, and what predicts it.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Emotional Recognition: A Comparative Study of People with Mild Cognitive Impairment and Alzheimer’s Disease Self-Report with Caregiver Perspectives

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Geriatric Psychiatry and Neurology 2025-05-06

Participants across all groups showed significant differences in cognition and functionality. 5 key findings →

Participants: 141 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of Magnetic Resonance Spectroscopy ( MRS ), Diffusion‐Tensor‐Imaging ( DTI ) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Magnetic Resonance Imaging 2026-03-19

Alzheimer's disease (AD) is one of the most common neurological disorders affecting older adults, with approximately 7.2 million cases only in the United States. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Detection of Alzheimer and mild cognitive impairment patients by Poincare and Entropy methods based on electroencephalography signals

✓ Peer-reviewed alzhub usefulness score 36 out of 100. BioMedical Engineering OnLine 2025-04-24

Alzheimer's disease (AD) is characterized by deficits in cognition, behavior, and intellectual functioning, and Mild Cognitive Impairment (MCI) refers to individuals whose cognitive impairment deviates from what is expected for their age but does not significantly interfere with daily activities. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prediction of mild cognitive impairment using blood multi-omics data

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Frontiers in Genetics 2025-05-26

Mild cognitive impairment (MCI) represents an initial phase of memory or other cognitive function decline and is viewed as an intermediary stage between normal aging and Alzheimer's disease (AD), the most prevalent type of dementia. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Early Dysregulation of RNA Splicing and Translation Processes Are Key Markers from Mild Cognitive Impairment to Alzheimer’s Disease: An In Silico Transcriptomic Analysis

✓ Peer-reviewed alzhub usefulness score 36 out of 100. International Journal of Molecular Sciences 2025-07-28

About one billion people worldwide are affected by neurologic disorders. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Transcriptome-informed metabolic modeling reveals astrocyte-specific vulnerabilities in mild cognitive impairment and Alzheimer’s disease progression

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Frontiers in Bioinformatics 2026-06-02

The analyses supported stage-dependent remodeling of astrocyte-associated transcriptional and metabolic programs during disease progression. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognitive tasks for evoking the P300 event-related potential in Alzheimer's disease and mild cognitive impairment: A scoping review

✓ Peer-reviewed alzhub usefulness score 36 out of 100. International Journal of Psychophysiology 2026-05-25

Event-related potentials (ERPs), particularly the P300 component, provide a noninvasive, cost-effective approach to probing neural dysfunction in Alzheimer's disease (AD) and mild cognitive impairment (MCI). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Blood level of β-amyloid, Tau, and p-Tau in mild cognitive impairment and Alzheimer disease: A follow up study

✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Indian Journal of Medical Research 2026-03-24

Comparison of proteins between the three groups revealed significantly lower Aβ1-42, higher Tau and pTau protein expression in serum of patients with Alzheimer disease as compared to patients with mild cognitive impairment and controls. 4 key findings →

Participants: 96 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cost-utility analysis of cerebrospinal fluid versus blood biomarkers for early detection of Alzheimer’s disease and mild cognitive impairment in Thailand: a modeling study

✓ Peer-reviewed alzhub usefulness score 36 out of 100. BMC Health Services Research 2026-04-02

Compared with no testing, the CSF strategy yielded 0.011 additional life-years and 0.019 additional QALYs for an extra cost of THB2,589 (USD71), resulting in an ICER of THB132,961 (USD3,632) per QALY. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuroprotective, Antioxidant and Anti-Inflammatory Effect of Greek Pomegranate Seed Oil on N2a Neuroblastoma Cells and Mild Cognitive Impairment Patients

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Biology 2025-05-15

Alzheimer’s disease (AD) remains a significant global health challenge with limited FDA-approved treatments, necessitating the search for novel preventive strategies. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Detecting Mild Cognitive Impairment to Alzheimer’s Disease Progression by fMRI Using Convolutional Neural Network and Long-short Term Memory

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Basic and Clinical Neuroscience Journal 2025-11-01

The results showed that the best validation scores were achieved by the CNN-LSTM model after integrating clinical attributes, with an accuracy of 92.47%. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Disease progression from mild cognitive impairment to dementia for patients with Alzheimer's disease or Lewy body pathology

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Journal of Alzheimer s Disease Reports 2025-07-10

We found that orientation, memory, and irritability scores were useful in predicting AD dementia onset, while daily living, depression, and executive function scores were identified as strong predictors in the LB cohort. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Acupuncture modulates the microbiota-gut-brain axis: a novel therapeutic strategy for amnestic mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Frontiers in Neuroscience 2025-11-13

Amnestic mild cognitive impairment (aMCI) represents a critical prodromal stage of Alzheimer's disease (AD), yet effective therapeutic interventions to prevent or delay this conversion remain an unmet clinical need. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer’s disease: the need for rigor

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s Research & Therapy 2025-02-01

We consider the recent publication by Ornish and colleagues and the rigor expected for interventional clinical trials. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Application of Upper Limb Multimodal Tasks Combined With fNIRS Technology in the Assessment of Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Journal of Biophotonics 2025-05-14

Mild cognitive impairment (MCI) is primarily characterized by a gradual decline in cognitive function, where early detection and intervention are crucial to preventing Alzheimer's disease progression. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Nanocarrier-based drug delivery for mild cognitive impairment: Extracellular vesicles and carbon nanotubes as emerging therapeutic tools

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Biomedicine & Pharmacotherapy 2025-08-07

Mild cognitive impairment (MCI) is the in-between stage between healthy cognitive aging and neurodegenerative diseases such as Alzheimer's disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Conversion to Mild Cognitive Impairment and Alzheimer’s Disease Dementia Related to Apathy, APOE Genotype and Antidepressant Use

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Journal of Geriatric Psychiatry and Neurology 2025-04-14

Our findings support apathy and APOE ε4 as robust predictors of conversion to MCI and ADD, and demonstrate novel associations between antidepressant use and conversion. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed